Ipsen SA (IPN)

Currency in EUR
106.50
+1.20(+1.14%)
Closed·
IPN Scorecard
Full Analysis
Net income is expected to grow this year
IPN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
104.60106.50
52 wk Range
87.95125.60
Key Statistics
Prev. Close
105.3
Open
105
Day's Range
104.6-106.5
52 wk Range
87.95-125.6
Volume
54.23K
Average Volume (3m)
75.95K
1-Year Change
1.84%
Book Value / Share
51.19
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IPN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
127.00
Upside
+19.25%
Members' Sentiments
Bearish
Bullish
ProTips
Valuation implies a strong free cash flow yield

Ipsen SA News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Ipsen SA Company Profile

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.

Employees
5358
Market
France

Ipsen SA Earnings Call Summary for Q1/2025

  • Q1 2025 revenue of $918.8M exceeded forecasts by 13.7%, with total sales up 11.6% YoY; stock fell 3.23% despite strong earnings
  • Oncology sales grew 8%, rare disease saw significant growth, neuroscience approached double-digit growth; company maintains PFIC leadership
  • Ipsen reaffirmed 2025 guidance: total sales growth over 5% at constant exchange rates, core operating margin exceeding 30% of sales
  • CEO highlighted strong top-line growth, increased investment in launches and pipeline; key milestones include EMA decision on Cabometyx
  • Challenges: generic competition for Somatuline, potential US aesthetics market softening; manufacturing primarily in Europe mitigates tariff concerns
Last Updated: 16/04/2025, 14:02
Read Full Transcript

Compare IPN to Peers and Sector

Metrics to compare
IPN
Peers
Sector
Relationship
P/E Ratio
19.4x22.3x−0.5x
PEG Ratio
−0.570.100.00
Price/Book
2.1x3.7x2.6x
Price / LTM Sales
2.3x2.1x3.3x
Upside (Analyst Target)
14.9%9.8%43.5%
Fair Value Upside
Unlock16.7%6.9%Unlock

Analyst Ratings

7 Buy
6 Hold
1 Sell
Ratings:
14 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 127.00
(+19.25% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 5.42%
Dividend Yield
1.33%
Industry Median 4.37%
Annualised payout
1.40
Paid annually
5-Years Growth
+6.96%
Growth Streak

Earnings

Latest Release
Jul 31, 2025
EPS / Forecast
4.00 / --
Revenue / Forecast
901.00M / 917.00M
EPS Revisions
Last 90 days

IPN Income Statement

People Also Watch

252.20
ESLX
+1.16%
27.58
DAST
+0.22%
31.29
MICP
+1.89%
70.46
TEPRF
+3.62%
461.10
LVMH
+0.74%

FAQ

What Stock Exchange Does Ipsen Trade On?

Ipsen is listed and trades on the Paris Stock Exchange stock exchange.

What Is the Stock Symbol for Ipsen?

The stock symbol for Ipsen is "IPN."

What Is the Ipsen Market Cap?

As of today, Ipsen market cap is 8.78B.

What Is Ipsen's Earnings Per Share (TTM)?

The Ipsen EPS (TTM) is 5.42.

When Is the Next Ipsen Earnings Date?

Ipsen will release its next earnings report on 21 Oct 2025.

From a Technical Analysis Perspective, Is IPN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Ipsen Stock Split?

Ipsen has split 0 times.

How Many Employees Does Ipsen Have?

Ipsen has 5358 employees.

What is the current trading status of Ipsen (IPN)?

As of 07 Aug 2025, Ipsen (IPN) is trading at a price of 106.50, with a previous close of 105.30. The stock has fluctuated within a day range of 104.60 to 106.50, while its 52-week range spans from 87.95 to 125.60.

What Is Ipsen (IPN) Price Target According to Analysts?

The average 12-month price target for Ipsen is EUR127, with a high estimate of EUR155 and a low estimate of EUR105. 7 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +19.25% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.